ALS costs may reach $1.02B each year in US, study finds
There are currently up to 18,000 people living with amyotrophic lateral sclerosis (ALS) in the U.S., with national costs…
Articles by Margarida Maia, PhD
Phase 2 trial of cortisol modulator for ALS still enrolling patients
Enrollment is still ongoing for a Phase 2 clinical trial testing the safety and efficacy of Corcept Therapeutics‘ cortisol…
Pridopidine shows some potential in HEALEY trial, but misses main goal
Pridopidine, an oral small molecule, failed to meet its primary goal of improving physical function across amyotrophic lateral sclerosis…
AstroRx slows ALS progression in Phase 1/2 study
Kadimastem’s experimental cell-based therapy AstroRx was safe and significantly slowed disease progression in the first three months among…
Intravenous Ibudilast Safe, Tolerated Well Among Healthy Volunteers
A new formulation of MediciNova’s investigational amyotrophic lateral sclerosis treatment ibudilast (MN-166) given via an intravenous (into the…
ANX005 Slows ALS Progression in Phase 2a Study
ANX005, an experimental medication being developed by Annexon Biosciences for neurodegenerative and autoimmune diseases, resulted in a slowing of…
Masitinib Gains Orphan Drug Status for ALS in Switzerland
Masitinib, an oral medicine developed by AB Science, has won orphan drug status for treating amyotrophic lateral…
Low-dose Aldesleukin Slows ALS Progression, Extends Survival: Trial
A low dose of aldesleukin, an immunotherapy approved for certain cancers, slowed disease progression and significantly improved survival in people…
DNL343 Well-tolerated by ALS Patients, Interim Data Show
DNL343, an investigational oral small molecule developed by Denali Therapeutics, can extensively enter the brain and reduce the cellular…
NP001 May Slow ALS Progression by Limiting ‘Leaks’ of Gut Bacteria
Neuvivo’s NP001 (sodium chlorite) may help slow the progression of amyotrophic lateral sclerosis (ALS) by taming the systemic inflammation…